Cadrenal Therapeutics Plans Phase 2a Trial for CAD-1005 to Address Acute Kidney Injury
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- New Indication Expansion: CAD-1005's addition of the Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) indication targets a market affecting 35,000 U.S. patients annually, representing a $1 billion opportunity and addressing a significant gap in FDA-approved therapies, thereby creating substantial commercial prospects for Cadrenal Therapeutics.
- Clinical Trial Plans: The planned Phase 2a trial, set to begin in 2026, aims to evaluate the safety and efficacy of CAD-1005 in high-risk cardiac surgery patients, which is expected to provide critical data supporting the company's strategic partnerships in both acute kidney injury and thrombotic conditions.
- Capital Efficiency Enhancement: This trial leverages existing hospital ICU infrastructure and an intravenous formulation to offer an efficient critical care solution, aimed at attracting global pharmaceutical partners and further enhancing Cadrenal's market position.
- Strategic Collaboration Opportunities: Cadrenal plans to discuss the CSA-AKI clinical strategy and its implications for CAD-1005's broader development at the 2026 BIO International Convention, which is anticipated to create favorable conditions for securing non-dilutive collaborations to support pipeline expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVKD
About CVKD
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cadrenal Therapeutics Plans Phase 2a Trial for CAD-1005 to Address Acute Kidney Injury
- New Indication Expansion: CAD-1005's addition of the Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) indication targets a market affecting 35,000 U.S. patients annually, representing a $1 billion opportunity and addressing a significant gap in FDA-approved therapies, thereby creating substantial commercial prospects for Cadrenal Therapeutics.
- Clinical Trial Plans: The planned Phase 2a trial, set to begin in 2026, aims to evaluate the safety and efficacy of CAD-1005 in high-risk cardiac surgery patients, which is expected to provide critical data supporting the company's strategic partnerships in both acute kidney injury and thrombotic conditions.
- Capital Efficiency Enhancement: This trial leverages existing hospital ICU infrastructure and an intravenous formulation to offer an efficient critical care solution, aimed at attracting global pharmaceutical partners and further enhancing Cadrenal's market position.
- Strategic Collaboration Opportunities: Cadrenal plans to discuss the CSA-AKI clinical strategy and its implications for CAD-1005's broader development at the 2026 BIO International Convention, which is anticipated to create favorable conditions for securing non-dilutive collaborations to support pipeline expansion.
See More
Cadrenal Therapeutics Q1 Financial Results
- Net Loss Reported: Cadrenal Therapeutics reported a net loss of $2.5 million for Q1 2026, indicating challenges in profitability that could impact investor confidence and future funding capabilities.
- Cash Position: As of March 31, 2026, Cadrenal had cash and cash equivalents of $2.3 million, reflecting tight liquidity that may limit ongoing operations and research and development activities.
- Financial Transparency: The company's release of financial information and historical earnings data provides investors with a clearer view of its financial status, although the current losses may raise concerns about long-term sustainability.
- Market Reaction Anticipation: Following the earnings report, the market may focus more on Cadrenal's future development direction and financing strategies, especially in the current economic climate where investors will be more cautious in assessing risks associated with biotech firms.
See More
Cadrenal Therapeutics Reports Q1 2026 Financial Results and CAD-1005 Program Update
- FDA Meeting Outcomes: Cadrenal Therapeutics received critical trial design guidance from the FDA during its EOP2 meeting, planning to advance directly to a randomized, blinded, placebo-controlled Phase 3 trial for CAD-1005, which is expected to support a New Drug Application submission in 2029.
- Clinical Trial Scale: The planned Phase 3 study will enroll approximately 120 patients to evaluate the efficacy of CAD-1005 added to standard anticoagulation, with the primary endpoint being the incidence of new or worsening thrombotic events, showcasing the company's strategic foresight in HIT treatment.
- R&D Expense Reduction: Research and development expenses for Q1 2026 were $0.8 million, significantly down from $1.7 million in Q1 2025, indicating progress in cost control, while the net loss decreased to $2.5 million, reflecting an improvement in financial health.
- Financing Support: Following the end of Q1 2026, Cadrenal completed a $2.5 million financing, providing essential capital for the upcoming Phase 3 clinical trial, further solidifying its market position in HIT treatment.
See More
Cadrenal Advances CAD-1005 to Phase 3 Trial Following FDA Clearance
- FDA Approval for Phase 3: Cadrenal Therapeutics' CAD-1005 has received FDA clearance to advance into a Phase 3 randomized controlled trial for heparin-induced thrombocytopenia, with plans to enroll approximately 120 patients, indicating a significant strategic advancement in the development of new therapies.
- Phase 2 Trial Data: Although the Phase 2 trial missed its primary endpoint, CAD-1005 demonstrated over a 25% reduction in thrombotic events when combined with standard anticoagulant therapy, suggesting its potential clinical value and the possibility of transforming HIT treatment.
- Pipeline Expansion: Cadrenal is expanding its 12-LOX drug pipeline while maintaining a focus on CAD-1005; early research indicates that targeting the 12-LOX pathway may have applications in obesity and diabetes, enhancing the company's competitive position in the market.
- Retail Sentiment Surge: Retail sentiment for CVKD reached a record high of 99/100 on Stocktwits, reflecting strong investor confidence in the company's future despite a 62% decline in stock price over the past year, highlighting market expectations for its new therapy.
See More
CAD-1005 Advances to Pivotal Phase 3 Clinical Trial
- Regulatory Milestone: Cadrenal Therapeutics achieved a significant milestone by receiving critical guidance from the FDA during its EOP2 meeting, successfully advancing CAD-1005 into pivotal Phase 3 trials, marking a major step in treating heparin-induced thrombocytopenia (HIT).
- Trial Design: The planned Phase 3 study will enroll approximately 120 patients across 50 clinical centers worldwide, aiming to evaluate the efficacy of CAD-1005 in conjunction with standard anticoagulant therapy, with a projected NDA submission in 2029.
- Efficacy Data: Phase 2 trial results indicated that the addition of CAD-1005 led to over a 25% absolute reduction in thrombotic events, demonstrating its potential to improve patient outcomes and possibly becoming the first new therapy in over two decades.
- Market Potential: As the first novel treatment targeting HIT, CAD-1005 has received Orphan Drug and Fast Track designations, positioning it to fill a significant market gap for the over 12 million patients receiving heparin annually in the U.S.
See More
H.C. Wainwright Lowers Target Price for Cadrenal Therapeutics Inc. to $13 from $32
- Company Overview: Cadrénal Therapeutics is a company focused on developing innovative therapies.
- Recent Price Adjustment: The target price for Cadrénal Therapeutics has been cut from $32 to $13.
See More
Cadrenal Therapeutics Plans Phase 2a Trial for CAD-1005 to Address Acute Kidney Injury
- New Indication Expansion: CAD-1005's addition of the Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) indication targets a market affecting 35,000 U.S. patients annually, representing a $1 billion opportunity and addressing a significant gap in FDA-approved therapies, thereby creating substantial commercial prospects for Cadrenal Therapeutics.
- Clinical Trial Plans: The planned Phase 2a trial, set to begin in 2026, aims to evaluate the safety and efficacy of CAD-1005 in high-risk cardiac surgery patients, which is expected to provide critical data supporting the company's strategic partnerships in both acute kidney injury and thrombotic conditions.
- Capital Efficiency Enhancement: This trial leverages existing hospital ICU infrastructure and an intravenous formulation to offer an efficient critical care solution, aimed at attracting global pharmaceutical partners and further enhancing Cadrenal's market position.
- Strategic Collaboration Opportunities: Cadrenal plans to discuss the CSA-AKI clinical strategy and its implications for CAD-1005's broader development at the 2026 BIO International Convention, which is anticipated to create favorable conditions for securing non-dilutive collaborations to support pipeline expansion.
See More
Cadrenal Therapeutics Q1 Financial Results
- Net Loss Reported: Cadrenal Therapeutics reported a net loss of $2.5 million for Q1 2026, indicating challenges in profitability that could impact investor confidence and future funding capabilities.
- Cash Position: As of March 31, 2026, Cadrenal had cash and cash equivalents of $2.3 million, reflecting tight liquidity that may limit ongoing operations and research and development activities.
- Financial Transparency: The company's release of financial information and historical earnings data provides investors with a clearer view of its financial status, although the current losses may raise concerns about long-term sustainability.
- Market Reaction Anticipation: Following the earnings report, the market may focus more on Cadrenal's future development direction and financing strategies, especially in the current economic climate where investors will be more cautious in assessing risks associated with biotech firms.
See More
Cadrenal Therapeutics Reports Q1 2026 Financial Results and CAD-1005 Program Update
- FDA Meeting Outcomes: Cadrenal Therapeutics received critical trial design guidance from the FDA during its EOP2 meeting, planning to advance directly to a randomized, blinded, placebo-controlled Phase 3 trial for CAD-1005, which is expected to support a New Drug Application submission in 2029.
- Clinical Trial Scale: The planned Phase 3 study will enroll approximately 120 patients to evaluate the efficacy of CAD-1005 added to standard anticoagulation, with the primary endpoint being the incidence of new or worsening thrombotic events, showcasing the company's strategic foresight in HIT treatment.
- R&D Expense Reduction: Research and development expenses for Q1 2026 were $0.8 million, significantly down from $1.7 million in Q1 2025, indicating progress in cost control, while the net loss decreased to $2.5 million, reflecting an improvement in financial health.
- Financing Support: Following the end of Q1 2026, Cadrenal completed a $2.5 million financing, providing essential capital for the upcoming Phase 3 clinical trial, further solidifying its market position in HIT treatment.
See More
Cadrenal Advances CAD-1005 to Phase 3 Trial Following FDA Clearance
- FDA Approval for Phase 3: Cadrenal Therapeutics' CAD-1005 has received FDA clearance to advance into a Phase 3 randomized controlled trial for heparin-induced thrombocytopenia, with plans to enroll approximately 120 patients, indicating a significant strategic advancement in the development of new therapies.
- Phase 2 Trial Data: Although the Phase 2 trial missed its primary endpoint, CAD-1005 demonstrated over a 25% reduction in thrombotic events when combined with standard anticoagulant therapy, suggesting its potential clinical value and the possibility of transforming HIT treatment.
- Pipeline Expansion: Cadrenal is expanding its 12-LOX drug pipeline while maintaining a focus on CAD-1005; early research indicates that targeting the 12-LOX pathway may have applications in obesity and diabetes, enhancing the company's competitive position in the market.
- Retail Sentiment Surge: Retail sentiment for CVKD reached a record high of 99/100 on Stocktwits, reflecting strong investor confidence in the company's future despite a 62% decline in stock price over the past year, highlighting market expectations for its new therapy.
See More
CAD-1005 Advances to Pivotal Phase 3 Clinical Trial
- Regulatory Milestone: Cadrenal Therapeutics achieved a significant milestone by receiving critical guidance from the FDA during its EOP2 meeting, successfully advancing CAD-1005 into pivotal Phase 3 trials, marking a major step in treating heparin-induced thrombocytopenia (HIT).
- Trial Design: The planned Phase 3 study will enroll approximately 120 patients across 50 clinical centers worldwide, aiming to evaluate the efficacy of CAD-1005 in conjunction with standard anticoagulant therapy, with a projected NDA submission in 2029.
- Efficacy Data: Phase 2 trial results indicated that the addition of CAD-1005 led to over a 25% absolute reduction in thrombotic events, demonstrating its potential to improve patient outcomes and possibly becoming the first new therapy in over two decades.
- Market Potential: As the first novel treatment targeting HIT, CAD-1005 has received Orphan Drug and Fast Track designations, positioning it to fill a significant market gap for the over 12 million patients receiving heparin annually in the U.S.
See More
H.C. Wainwright Lowers Target Price for Cadrenal Therapeutics Inc. to $13 from $32
- Company Overview: Cadrénal Therapeutics is a company focused on developing innovative therapies.
- Recent Price Adjustment: The target price for Cadrénal Therapeutics has been cut from $32 to $13.
See More
